- Arcutis Biotherapeutics (NASDAQ:ARQT) has commenced pivotal Phase 3 clinical trials evaluating topical roflumilast cream ARQ-151 as a potential treatment for atopic dermatitis.
- “More than 19M people in the U.S. suffer from atopic dermatitis, of which at least 60% are young children, thereby making safety and tolerability particularly important in this disease,” said Patrick Burnett, M.D., Ph.D., FAAD, Arcutis’ Chief Medical Officer.
- The Co. believe topical roflumilast has the potential to eliminate the need to compromise between safety, efficacy, and tolerability, and look forward to reporting topline data in the 2H 2022.
- In each trial, ~650 subjects are planned to be randomized 2:1 to either roflumilast cream 0.15% or matching vehicle cream.
